Overview

FRANCIS-ACS Trial: A Study of the Safety and Efficacy of A 002 in Subjects With Acute Coronary Syndromes

Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety and efficacy of A 002 when added to high dose atorvastatin in subjects with an acute coronary syndrome (ACS)
Phase:
Phase 2
Details
Lead Sponsor:
Anthera Pharmaceuticals
Treatments:
Atorvastatin
Atorvastatin Calcium
Varespladib methyl